M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease

MP Cañadell; D Moreno-Delgado; M Rodríguez-Ruiz; E Moreno; J Botta; P Gasperini; A Cordomí; LA Howell; G Navarro; V Casadó; S Ferré; M Guzmán; L Pardo; J Alberch; EI Canela; C Lluís; P J McCormick; S Ginés

doi:10.1136/jnnp-2014-309032.289

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Experimental therapeutics – preclinical

M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Cañadell M, Moreno-Delgado D, Rodríguez-Ruiz M, et al

M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease

Journal of Neurology, Neurosurgery & Psychiatry 2014;85:A100.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password